Safety and tolerability of Evusheld in patients with CVID : The Mayo Clinic experience
© 2023 The Authors..
Background: The past 2 years of the COVID-19 pandemic brought with it many unknowns for patients with immunodeficiency. Because of the concern for severe infection in those with immunocompromise, patients have been eager for effective prevention, vaccination, and treatment strategies. Preexposure prophylaxis provides another means of prevention in those with immunocompromise. A combination of tixagevimab and cilgavimab (Evusheld [AstraZeneca Cambridge, United Kingdom]) was granted emergency use authorization for preexposure prophylaxis at the end of 2021, but questions remained regarding how this would be tolerated and the side effects associated with its use.
Objectives: Our aim was to evaluate the safety and tolerability of Evusheld in patients with CVID from our tri-site institution.
Methods: We performed an institutional review board-approved, retrospective chart review of patients with common variable immunodeficiency (CVID) who received Evusheld before March 26, 2022.
Results: Of the 45 patients with CVID who received Evusheld, 41 (91%) received the recommended full dose of 600 mg. The majority of patients (39 of 45 [87%]) tolerated Evusheld without adverse events. The adverse events reported included immediate injection site pain, fatigue and cough, an episode of shingles, and chest pain.
Conclusions: This is an initial report on the safety and tolerability of Evusheld injections in patients with CVID. The majority of patients tolerated the injections without adverse events. For patients with reported chest pain, the results of a subsequent cardiac workup were negative. The efficacy of Evusheld could not be evaluated owing to the short median follow-up of this study (19 days).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. Global - 2(2023), 2 vom: 09. Mai, Seite 100081 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Squire, Jacqueline D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 14.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jacig.2023.100081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352864923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352864923 | ||
| 003 | DE-627 | ||
| 005 | 20231226054710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacig.2023.100081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352864923 | ||
| 035 | |a (NLM)36777105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Squire, Jacqueline D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and tolerability of Evusheld in patients with CVID |b The Mayo Clinic experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: The past 2 years of the COVID-19 pandemic brought with it many unknowns for patients with immunodeficiency. Because of the concern for severe infection in those with immunocompromise, patients have been eager for effective prevention, vaccination, and treatment strategies. Preexposure prophylaxis provides another means of prevention in those with immunocompromise. A combination of tixagevimab and cilgavimab (Evusheld [AstraZeneca Cambridge, United Kingdom]) was granted emergency use authorization for preexposure prophylaxis at the end of 2021, but questions remained regarding how this would be tolerated and the side effects associated with its use | ||
| 520 | |a Objectives: Our aim was to evaluate the safety and tolerability of Evusheld in patients with CVID from our tri-site institution | ||
| 520 | |a Methods: We performed an institutional review board-approved, retrospective chart review of patients with common variable immunodeficiency (CVID) who received Evusheld before March 26, 2022 | ||
| 520 | |a Results: Of the 45 patients with CVID who received Evusheld, 41 (91%) received the recommended full dose of 600 mg. The majority of patients (39 of 45 [87%]) tolerated Evusheld without adverse events. The adverse events reported included immediate injection site pain, fatigue and cough, an episode of shingles, and chest pain | ||
| 520 | |a Conclusions: This is an initial report on the safety and tolerability of Evusheld injections in patients with CVID. The majority of patients tolerated the injections without adverse events. For patients with reported chest pain, the results of a subsequent cardiac workup were negative. The efficacy of Evusheld could not be evaluated owing to the short median follow-up of this study (19 days) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID | |
| 650 | 4 | |a COVID-19, Coronavirus disease 2019 | |
| 650 | 4 | |a CVID | |
| 650 | 4 | |a CVID, Common variable immunodeficiency | |
| 650 | 4 | |a ED, Emergency department | |
| 650 | 4 | |a EUA, Emergency use authorization | |
| 650 | 4 | |a Evusheld | |
| 650 | 4 | |a SAE, Serious adverse event | |
| 650 | 4 | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a immunocompromise | |
| 700 | 1 | |a Pitlick, Mitchell M |e verfasserin |4 aut | |
| 700 | 1 | |a Freeman, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Avni Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. Global |d 2022 |g 2(2023), 2 vom: 09. Mai, Seite 100081 |w (DE-627)NLM345686632 |x 2772-8293 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2023 |g number:2 |g day:09 |g month:05 |g pages:100081 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacig.2023.100081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2023 |e 2 |b 09 |c 05 |h 100081 | ||